story of the week
R-CHOP-21 Remains Standard First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone in Patients With Newly Diagnosed Diffuse Large B-Cell Non-Hodgkin Lymphoma: A Phase 3 Comparison of Dose Intensification With 14-Day Versus 21-Day Cycles
Lancet 2013 Apr 22;[EPub Ahead of Print], D Cunningham, EA Hawkes, A Jack, et alFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.